Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

Authors Zheng J, Zhong N, Newlands AH, Church A, Goh AH

Received 17 January 2015

Accepted for publication 11 May 2015

Published 2 September 2015 Volume 2015:10(1) Pages 1753—1767


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Jinping Zheng,1 Nanshan Zhong,1 Amy Newlands,2 Alison Church,3 Aik H Goh4

1State Key Lab of Respiratory Disease, National Clinical Research Centre of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 2GlaxoSmithKline, London, UK; 3GlaxoSmithKline, Research Triangle Park, NC, USA; 4GlaxoSmithKline, Shanghai, People’s Republic of China

Background: Combination of the inhaled long-acting muscarinic antagonist umeclidinium (UMEC; GSK573719) with the long-acting β2-agonist vilanterol (VI) is an approved maintenance treatment for COPD in the US and EU. We compared the efficacy and safety of UMEC/VI with placebo in patients with COPD of Asian ancestry.
Patients and methods: In this 24-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were randomized 1:1:1 to UMEC/VI 125/25 µg, UMEC/VI 62.5/25 µg, or placebo. The primary efficacy end point was trough forced expiratory volume in 1 second (FEV1) on day 169; secondary end points were Transition Dyspnea Index (TDI) focal score at week 24 and weighted mean (WM) FEV1 over 0–6 hours postdose on day 1. Additional end points and safety were also assessed.
Results: Both UMEC/VI 125/25 µg and UMEC/VI 62.5/25 mg statistically significantly improved trough FEV1 at day 169 versus placebo (UMEC/VI 125/25 µg, 0.216 L, [95% confidence interval [CI] 0.175–0.257]; UMEC/VI 62.5/25 µg, 0.151 L, 95% CI 0.110–0.191; both P<0.001). Statistically significant improvements in TDI score were observed for both UMEC/VI groups versus placebo (UMEC/VI 125/25 µg, 0.9, 95% CI 0.3–1.4, P=0.002; UMEC/VI 62.5/25 µg, 0.7, 95% CI 0.1–1.2, P=0.016). On day 1, both UMEC/VI groups improved 0–6-hour WM FEV1 versus placebo (UMEC/VI 125/25 µg, 0.182 L 95% CI 0.161–0.203; UMEC/VI 62.5/25 µg, 0.160 L, 95% CI 0.139–0.181; both P<0.001). Statistically significant improvements for UMEC/VI groups versus placebo were observed for rescue albuterol use at weeks 1–24 (puffs/day, both P<0.001). The incidence of adverse events was similar across groups.
Conclusion: In Asian patients with COPD, once-daily UMEC/VI 125/25 µg and UMEC 62.5/25 µg resulted in clinically meaningful and statistically significant improvements in lung-function end points versus placebo. Symptomatic and quality of life measures also improved. The safety profile of UMEC/VI was consistent with previous studies.

Keywords: chronic obstructive pulmonary disease, umeclidinium, vilanterol, Asian

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis

Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1863-1881

Published Date: 9 September 2015

Epidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, Russia

Artyukhov IP, Arshukova IL, Dobretsova EA, Dugina TA, Shulmin AV, Demko IV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1781-1786

Published Date: 2 September 2015

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1673-1683

Published Date: 20 August 2015

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

D’Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D’Andrea P, Hu H, Goyal P, Altman P

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1599-1612

Published Date: 11 August 2015

Thiazolidinediones are associated with a reduced risk of COPD exacerbations

Rinne ST, Liu CF, Feemster LC, Collins BF, Bryson CL, O’Riordan TG, Au DH

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1591-1597

Published Date: 10 August 2015

Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction

Mahmood MQ, Sohal SS, Shukla SD, Ward C, Hardikar A, Noor WD, Muller HK, Knight DA, Walters EH

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1515-1524

Published Date: 4 August 2015

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1015-1026

Published Date: 5 June 2015

The reasons for triple therapy in stable COPD patients in Japanese clinical practice

Miyazaki M, Nakamura H, Takahashi S, Chubachi S, Sasaki M, Haraguchi M, Terai H, Ishii M, Fukunaga K, Tasaka S, Soejima K, Asano K, Betsuyaku T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1053-1059

Published Date: 4 June 2015